Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company engaged in developing a novel therapeutic product for the treatment of migraine. Its product candidate, STS101, is a drug-device combination of a dry-powder formulation of dihydroergotamine mesylate, or DHE, which can be self-administered with a pre-filled, single-use, nasal delivery device.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Satsuma Pharmaceuticals Inc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Satsuma Pharmaceuticals Inc market cap is $36.47M.
What is the 52-week high for Satsuma Pharmaceuticals Inc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Satsuma Pharmaceuticals Inc 52 week high is $8.08 as of September 11, 2025.
What is the 52-week low for Satsuma Pharmaceuticals Inc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Satsuma Pharmaceuticals Inc 52 week low is $0.59 as of September 11, 2025.
What is Satsuma Pharmaceuticals Inc stock price today?
Satsuma Pharmaceuticals Inc stock price today is $1.10.
What was Satsuma Pharmaceuticals Inc stock price yesterday?
Satsuma Pharmaceuticals Inc stock price yesterday was $1.11.
What is the PE ratio of Satsuma Pharmaceuticals Inc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Satsuma Pharmaceuticals Inc’s P/E ratio is -0.55.
What is the Price-to-Book ratio of Satsuma Pharmaceuticals Inc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Satsuma Pharmaceuticals Inc P/B ratio is 0.9687.
What is Satsuma Pharmaceuticals Inc's EBITDA?
EBITDA is a widely used measure of corporate profitability. It stands for Earnings before Interest, Taxes, Depreciation, and Amortization. It attempts to reflect the cash profit generated by a company’s operations. Satsuma Pharmaceuticals Inc's EBITDA is 0.34.
What is the 50-day moving average of Satsuma Pharmaceuticals Inc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Satsuma Pharmaceuticals Inc 50-day moving average is $0.9776.
